HU226812B1 - Enzymatically divisible dye compounds for diagnosis with near infrared light - Google Patents
Enzymatically divisible dye compounds for diagnosis with near infrared light Download PDFInfo
- Publication number
- HU226812B1 HU226812B1 HU0003132A HUP0003132A HU226812B1 HU 226812 B1 HU226812 B1 HU 226812B1 HU 0003132 A HU0003132 A HU 0003132A HU P0003132 A HUP0003132 A HU P0003132A HU 226812 B1 HU226812 B1 HU 226812B1
- Authority
- HU
- Hungary
- Prior art keywords
- formula
- dye
- defined above
- compound
- compounds according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 44
- 238000003745 diagnosis Methods 0.000 title description 4
- -1 carbopeptidases Proteins 0.000 claims description 21
- 238000010521 absorption reaction Methods 0.000 claims description 13
- 229920002521 macromolecule Polymers 0.000 claims description 9
- 230000005855 radiation Effects 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 4
- 108010039918 Polylysine Proteins 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229920000656 polylysine Polymers 0.000 claims description 4
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 2
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 108090001090 Lectins Proteins 0.000 claims description 2
- 102000004856 Lectins Human genes 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 150000001719 carbohydrate derivatives Chemical class 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 230000001085 cytostatic effect Effects 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims description 2
- 229920000736 dendritic polymer Polymers 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 150000002224 folic acids Chemical class 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 150000002482 oligosaccharides Polymers 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229950000688 phenothiazine Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 150000003230 pyrimidines Chemical class 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 229920002477 rna polymer Polymers 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 125000004964 sulfoalkyl group Chemical group 0.000 claims description 2
- 150000004043 trisaccharides Chemical class 0.000 claims description 2
- 229940075420 xanthine Drugs 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims 4
- 108091005804 Peptidases Proteins 0.000 claims 4
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 4
- 102000005600 Cathepsins Human genes 0.000 claims 2
- 108010084457 Cathepsins Proteins 0.000 claims 2
- 102000005575 Cellulases Human genes 0.000 claims 2
- 108010084185 Cellulases Proteins 0.000 claims 2
- 102000004882 Lipase Human genes 0.000 claims 2
- 108090001060 Lipase Proteins 0.000 claims 2
- 239000004367 Lipase Substances 0.000 claims 2
- 102000004316 Oxidoreductases Human genes 0.000 claims 2
- 108090000854 Oxidoreductases Proteins 0.000 claims 2
- 102000016387 Pancreatic elastase Human genes 0.000 claims 2
- 108010067372 Pancreatic elastase Proteins 0.000 claims 2
- 102000015439 Phospholipases Human genes 0.000 claims 2
- 108010064785 Phospholipases Proteins 0.000 claims 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 108091007187 Reductases Proteins 0.000 claims 2
- 102000005262 Sulfatase Human genes 0.000 claims 2
- 102000016679 alpha-Glucosidases Human genes 0.000 claims 2
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 2
- 235000019421 lipase Nutrition 0.000 claims 2
- 235000019833 protease Nutrition 0.000 claims 2
- 108060007951 sulfatase Proteins 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 102000005367 Carboxypeptidases Human genes 0.000 claims 1
- 108010006303 Carboxypeptidases Proteins 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 150000003212 purines Chemical class 0.000 claims 1
- 239000000975 dye Substances 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000008363 phosphate buffer Substances 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- 238000006862 quantum yield reaction Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 229960004657 indocyanine green Drugs 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 150000004032 porphyrins Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- ORDGVWFOWIEHDB-UHFFFAOYSA-N 4-(aminomethyl)benzohydrazide Chemical compound NCC1=CC=C(C(=O)NN)C=C1 ORDGVWFOWIEHDB-UHFFFAOYSA-N 0.000 description 2
- GDQXMMLQFVXPGA-UHFFFAOYSA-N 4-(hydrazinesulfonyl)benzoic acid Chemical compound NNS(=O)(=O)C1=CC=C(C(O)=O)C=C1 GDQXMMLQFVXPGA-UHFFFAOYSA-N 0.000 description 2
- BDBMLMBYCXNVMC-UHFFFAOYSA-O 4-[(2e)-2-[(2e,4e,6z)-7-[1,1-dimethyl-3-(4-sulfobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS(O)(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C BDBMLMBYCXNVMC-UHFFFAOYSA-O 0.000 description 2
- WPBZMCGPFHZRHJ-UHFFFAOYSA-N 4-aminobenzohydrazide Chemical compound NNC(=O)C1=CC=C(N)C=C1 WPBZMCGPFHZRHJ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000012317 TBTU Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- IGDMSWAGZSSELR-UHFFFAOYSA-N 1,3-bis(4-aminophenyl)propan-2-one Chemical compound C1=CC(N)=CC=C1CC(=O)CC1=CC=C(N)C=C1 IGDMSWAGZSSELR-UHFFFAOYSA-N 0.000 description 1
- HYEWOLUMYHUCDE-UHFFFAOYSA-N 1,3-bis(4-hydrazinylphenyl)propan-2-one Chemical compound C1=CC(NN)=CC=C1CC(=O)CC1=CC=C(NN)C=C1 HYEWOLUMYHUCDE-UHFFFAOYSA-N 0.000 description 1
- KXMMNJQMGILZDB-UHFFFAOYSA-N 1-(2-oxopyridine-1-carbothioyl)pyridin-2-one Chemical compound O=C1C=CC=CN1C(=S)N1C(=O)C=CC=C1 KXMMNJQMGILZDB-UHFFFAOYSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- CQWJGMPBDQNEKC-UKCZNJPKSA-N 2-amino-9-n-[(3s,12r,15s,16r)-12-[(2s)-butan-2-yl]-4,7,10,16-tetramethyl-2,5,8,11,14-pentaoxo-3-propan-2-yl-1-oxa-4,7,10,13-tetrazacyclohexadec-15-yl]-4,6-dimethyl-3-oxo-1-n-[(3s,12r,15s,16r)-4,7,10,16-tetramethyl-2,5,8,11,14-pentaoxo-3,12-di(propan-2-yl) Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)CN(C)C(=O)[C@@H]([C@@H](C)CC)NC(=O)[C@H]1NC(=O)C1=CC=C(C)C2=C1N=C1C(C(=O)N[C@@H]3C(N[C@@H](C(=O)N(C)CC(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)C(C)C)=O)=C(N)C(=O)C(C)=C1O2 CQWJGMPBDQNEKC-UKCZNJPKSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 description 1
- ZNCFMBOWBMPEAC-UHFFFAOYSA-N 3,9-di(ethylidene)-2,4,8,10-tetraoxaspiro[5.5]undecane Chemical compound C1OC(=CC)OCC21COC(=CC)OC2 ZNCFMBOWBMPEAC-UHFFFAOYSA-N 0.000 description 1
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- SUTWPJHCRAITLU-UHFFFAOYSA-N 6-aminohexan-1-ol Chemical compound NCCCCCCO SUTWPJHCRAITLU-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003127 anti-melanomic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000017168 chlorine Nutrition 0.000 description 1
- 125000001309 chloro group Chemical class Cl* 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 108010002255 deoxyhemoglobin Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000003264 microelectrode measurement Methods 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 238000003333 near-infrared imaging Methods 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/02—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups
- C09B23/08—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines
- C09B23/086—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines more than five >CH- groups
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B69/00—Dyes not provided for by a single group of this subclass
- C09B69/10—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19717904A DE19717904A1 (de) | 1997-04-23 | 1997-04-23 | Sรคurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie |
| PCT/DE1998/001001 WO1998047538A2 (de) | 1997-04-23 | 1998-04-02 | Sรคurelabile und enzymatisch spaltbare farbstoffkonstrukte zur diagnostik mit nahinfrarotlicht und zur therapie |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0003132A2 HUP0003132A2 (hu) | 2001-01-29 |
| HUP0003132A3 HUP0003132A3 (en) | 2003-03-28 |
| HU226812B1 true HU226812B1 (en) | 2009-11-30 |
Family
ID=7827982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0003132A HU226812B1 (en) | 1997-04-23 | 1998-04-02 | Enzymatically divisible dye compounds for diagnosis with near infrared light |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6534041B1 (enExample) |
| EP (1) | EP0988060B1 (enExample) |
| JP (2) | JP5118790B2 (enExample) |
| KR (1) | KR100613306B1 (enExample) |
| CN (1) | CN1253507A (enExample) |
| AT (1) | ATE364404T1 (enExample) |
| AU (1) | AU733757B2 (enExample) |
| CA (1) | CA2287262C (enExample) |
| CY (1) | CY1106860T1 (enExample) |
| DE (2) | DE19717904A1 (enExample) |
| DK (1) | DK0988060T3 (enExample) |
| ES (1) | ES2289786T3 (enExample) |
| HU (1) | HU226812B1 (enExample) |
| NO (1) | NO327495B1 (enExample) |
| PT (1) | PT988060E (enExample) |
| WO (1) | WO1998047538A2 (enExample) |
Families Citing this family (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4445065A1 (de) * | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung |
| DE19717904A1 (de) * | 1997-04-23 | 1998-10-29 | Diagnostikforschung Inst | Sรคurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie |
| US6083486A (en) * | 1998-05-14 | 2000-07-04 | The General Hospital Corporation | Intramolecularly-quenched near infrared fluorescent probes |
| US6592847B1 (en) | 1998-05-14 | 2003-07-15 | The General Hospital Corporation | Intramolecularly-quenched near infrared flourescent probes |
| JP2000095758A (ja) | 1998-09-18 | 2000-04-04 | Schering Ag | ่ฟ่ตคๅค่ๅ ้ ๅฝฑๅคใใใณ่ๅ ้ ๅฝฑๆนๆณ |
| US7547721B1 (en) | 1998-09-18 | 2009-06-16 | Bayer Schering Pharma Ag | Near infrared fluorescent contrast agent and fluorescence imaging |
| US7175953B2 (en) | 1999-04-09 | 2007-02-13 | Institute Fuer Diagnostik Forschung | Short-warp peptide-dye conjugate as contrast agent for optical diagnostic |
| DE19917713A1 (de) * | 1999-04-09 | 2000-10-19 | Diagnostikforschung Inst | Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel fรผr die optische Diagnostik |
| US6114350A (en) * | 1999-04-19 | 2000-09-05 | Nen Life Science Products, Inc. | Cyanine dyes and synthesis methods thereof |
| FR2793414B1 (fr) * | 1999-05-10 | 2003-05-23 | Centre Nat Rech Scient | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules |
| WO2001089584A2 (en) * | 2000-05-23 | 2001-11-29 | Amersham Health As | Contrast agents |
| US7597878B2 (en) * | 2000-09-19 | 2009-10-06 | Li-Cor, Inc. | Optical fluorescent imaging |
| DE10046215B4 (de) | 2000-09-19 | 2004-04-15 | Institut fรผr Chemo- und Biosensorik Mรผnster e.V. i.Ins. | Fluorochrome und deren Verwendung |
| US20040180809A1 (en) * | 2000-10-16 | 2004-09-16 | Mallinckrodt Inc. | Tissue-specific exogenous optical agents |
| US6673334B1 (en) * | 2000-10-16 | 2004-01-06 | Mallinkcrodt, Inc. | Light sensitive compounds for instant determination of organ function |
| US20070092450A1 (en) * | 2000-10-16 | 2007-04-26 | Mallinckrodt Inc. | Tissue-specific exogenous optical agents |
| US6716413B1 (en) * | 2000-10-16 | 2004-04-06 | Mallinckrodt, Inc. | Indole compounds as tissue-specific exogenous optical agents |
| US7383076B2 (en) | 2000-11-27 | 2008-06-03 | The General Hospital Corporation | Fluorescence-mediated molecular tomography |
| US6984373B2 (en) | 2000-12-23 | 2006-01-10 | Dyax Corp. | Fibrin binding moieties useful as imaging agents |
| US20030044353A1 (en) * | 2001-01-05 | 2003-03-06 | Ralph Weissleder | Activatable imaging probes |
| US20030031627A1 (en) * | 2001-07-31 | 2003-02-13 | Mallinckrodt Inc. | Internal image antibodies for optical imaging and therapy |
| EP2014310B8 (en) | 2002-03-01 | 2012-12-26 | Dyax Corp. | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| EP1587944A4 (en) | 2002-03-01 | 2007-03-21 | Dyax Corp | KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES |
| US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
| EP1485716A1 (en) * | 2002-03-11 | 2004-12-15 | Visen Medical, Inc. | Optical imaging probes |
| GB0208989D0 (en) | 2002-04-19 | 2002-05-29 | Amersham Biosciences Uk Ltd | Methods for measuring enzyme activity |
| US7226577B2 (en) | 2003-01-13 | 2007-06-05 | Bracco Imaging, S. P. A. | Gastrin releasing peptide compounds |
| WO2004065491A1 (en) * | 2003-01-24 | 2004-08-05 | Schering Ag | Hydrophilic, thiol-reactive cyanine dyes and conjugates thereof with biomolecules for fluorescence diagnosis |
| ES2396368T3 (es) | 2003-03-03 | 2013-02-21 | Dyax Corporation | Pรฉptidos que se unen especรญficamente al receptor del HGF (CMET) y usos de los mismos |
| US20050106100A1 (en) * | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| JP2005170812A (ja) * | 2003-12-09 | 2005-06-30 | Konica Minolta Medical & Graphic Inc | ่ๅ ้ ๅฝฑๅคๅใณ่ๅ ้ ๅฝฑๆนๆณ |
| US7018775B2 (en) * | 2003-12-15 | 2006-03-28 | Eastman Kodak Company | Infrared absorbing N-alkylsulfate cyanine compounds |
| EP1901781A2 (en) * | 2005-06-21 | 2008-03-26 | Mallinckrodt, Inc. | Optical imaging contrast agents |
| US8227621B2 (en) * | 2005-06-30 | 2012-07-24 | Li-Cor, Inc. | Cyanine dyes and methods of use |
| EP1896086A1 (en) * | 2005-06-30 | 2008-03-12 | Bristol-Myers Squibb Pharma Company | Hydrazide conjugates as imaging agents |
| EP1745739A3 (en) * | 2005-07-14 | 2009-04-22 | Bundesrepublik Deutschland, vertr. d.d. Bundes- ministerium f. Wirtschaft- und Technologie, dieses vertr. d.d. Prรคs. d. Phys.-Techn. Bundesanstalt | Optical imaging of rheumatoid arthritis |
| JP5106397B2 (ja) | 2005-09-02 | 2012-12-26 | ใใปใณ ใกใใฃใซใซ๏ผ ใคใณใณใผใใฌใคใใใ | ็ไฝ้ฉๅๆง๏ฝ๏ผ๏ฝโไบ็ฝฎๆในใซใใณใขใใๅซๆ่ๅ ่ฒ็ด ๆจ่ญ |
| US7947256B2 (en) * | 2005-09-02 | 2011-05-24 | Visen Medical, Inc. | Biocompatible fluorescent imaging agents |
| US8173819B2 (en) * | 2005-09-02 | 2012-05-08 | Visen Medical, Inc. | Nicotinic and picolinic acid derived near-infrared fluorophores |
| DE102006029454A1 (de) | 2005-12-05 | 2007-06-06 | Dyomics Gmbh | Hydrophile Marker auf Basis von diasteromeren |
| US20070148094A1 (en) * | 2005-12-22 | 2007-06-28 | Uzgiris Egidijus E | Polymeric imaging agents and medical imaging methods |
| EP1973575B1 (en) | 2005-12-22 | 2019-07-24 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
| US9201063B2 (en) * | 2006-11-16 | 2015-12-01 | General Electric Company | Sequential analysis of biological samples |
| US7741045B2 (en) * | 2006-11-16 | 2010-06-22 | General Electric Company | Sequential analysis of biological samples |
| US7629125B2 (en) | 2006-11-16 | 2009-12-08 | General Electric Company | Sequential analysis of biological samples |
| US9333272B2 (en) | 2006-12-11 | 2016-05-10 | Bracco Imaging Spa | Fibrin binding peptide conjugates for diagnostic and therapeutic applications |
| ES2670852T3 (es) | 2007-02-09 | 2018-06-01 | Visen Medical, Inc. | Colorantes con policiclo y uso de los mismos |
| WO2008109832A2 (en) * | 2007-03-08 | 2008-09-12 | Visen Medical, Inc. | Viable near-infrared fluorochrome labeled cells and methods of making and using same |
| US7906106B2 (en) * | 2007-06-27 | 2011-03-15 | General Electric Company | In vivo cell trafficking |
| US8021647B2 (en) * | 2007-06-29 | 2011-09-20 | General Electric Company | In vivo optical imaging |
| AU2009205950C1 (en) | 2008-01-18 | 2015-08-06 | Visen Medical, Inc. | Fluorescent imaging agents |
| WO2009129220A2 (en) | 2008-04-14 | 2009-10-22 | The Gereral Hospital Corporation | Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
| EP2147684A1 (en) | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
| US7951959B2 (en) | 2008-09-17 | 2011-05-31 | Thermo Fisher Scientific (Milwaukee) LLC | Hydrophilic labels for biomolecules |
| US20110280806A1 (en) * | 2008-11-20 | 2011-11-17 | Robert James Domett Nairne | Dye conjugate imaging agents |
| US8864821B2 (en) | 2008-11-26 | 2014-10-21 | Visen Medical, Inc. | Methods and compositions for identifying subjects at risk of developing stent thrombosis |
| CA2758952C (en) * | 2009-04-17 | 2016-01-12 | Li-Cor, Inc. | Fluorescent imaging with substituted cyanine dyes |
| US9155471B2 (en) | 2009-05-27 | 2015-10-13 | Lumicell, Inc'. | Methods and systems for spatially identifying abnormal cells |
| US20110021908A1 (en) | 2009-05-27 | 2011-01-27 | Lumicell Diagnostics, Inc. | Methods and systems for spatially identifying abnormal cells |
| US20120226119A1 (en) | 2009-07-09 | 2012-09-06 | Hoffmann-La Roche Inc. | Vivo tumor vasculature imaging |
| CA2768330A1 (en) | 2009-07-28 | 2011-02-03 | F. Hoffmann-La Roche Ag | Non-invasive in vivo optical imaging method |
| EP2470887B1 (en) | 2009-08-28 | 2020-03-11 | VisEn Medical, Inc. | Systems for tomographic imaging in diffuse media using a hybrid inversion technique |
| CA2810822C (en) | 2009-09-22 | 2018-03-06 | Visen Medical, Inc. | Systems and methods for virtual index-matching of diffusive media |
| US9677125B2 (en) * | 2009-10-21 | 2017-06-13 | General Electric Company | Detection of plurality of targets in biological samples |
| EP2567234B1 (en) | 2010-05-07 | 2018-09-19 | F.Hoffmann-La Roche Ag | Diagnostic method for the detection of cells ex vivo |
| WO2012003334A2 (en) * | 2010-06-30 | 2012-01-05 | Case Western Reserve University | Molecular probes for imaging of myelin |
| US8524239B2 (en) | 2010-07-09 | 2013-09-03 | The United States of America as represented by the Secrectary, Department of Health and Human Services | Photosensitizing antibody-fluorophore conjugates |
| EP2618849B1 (en) | 2010-09-20 | 2020-10-21 | Caliper Life Sciences, Inc. | Multivalent fluorescent probes |
| WO2012054749A1 (en) | 2010-10-20 | 2012-04-26 | Li-Cor, Inc. | Cyanine dyes and their conjugates |
| WO2012058638A2 (en) | 2010-10-29 | 2012-05-03 | President And Fellows Of Harvard College | Nucleic acid nanostructure barcode probes |
| WO2012061403A1 (en) * | 2010-11-02 | 2012-05-10 | Life Technologies Corporation | Modified hydrocyanine dyes for the detection of reactive oxygen species |
| US9314304B2 (en) | 2010-12-08 | 2016-04-19 | Lumicell, Inc. | Methods and system for image guided cell ablation with microscopic resolution |
| EP2655327B1 (en) | 2010-12-21 | 2016-02-24 | Pierce Biotechnology, Inc. | Fluorescent compounds |
| US20140099264A1 (en) | 2011-03-07 | 2014-04-10 | F. Hoffman-La Roche Ag | Means and methods for in vivo testing of therapeutic antibodies |
| JP6385060B2 (ja) | 2011-03-07 | 2018-09-05 | ใจใใปใใใใณโใฉใปใญใทใฅใปใขใฏใใงใณใฒใผใซใทใฃใใ | ๆฒป็็ใซๆดปๆงใชๆไฝใฎใคใณใใใซใใใ้ธๆ |
| US20140080162A1 (en) | 2011-03-25 | 2014-03-20 | Almac Sciences (Scotland) Limited | Fluorescence lifetime epigenetics assays |
| AU2012253502C1 (en) | 2011-05-09 | 2017-12-14 | Visen Medical, Inc. | Carbonic anhydrase targeting agents and methods of using same |
| EP2731626B1 (en) * | 2011-07-11 | 2018-12-19 | THE UNITED STATES OF AMERICA, represented by the S | Photosensitizing antibody-fluorophore conjugates |
| US8889884B1 (en) | 2011-07-14 | 2014-11-18 | Pierce Biotechnology, Inc. | Phosphine derivatives of fluorescent compounds |
| US9249307B2 (en) | 2011-08-16 | 2016-02-02 | Pierce Biotechnology, Inc. | Benzocyanine compounds |
| EP2764406B1 (en) * | 2011-10-07 | 2018-03-14 | Cedars-Sinai Medical Center | Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties |
| US9751868B2 (en) | 2012-02-28 | 2017-09-05 | Pierce Biotechnology, Inc. | Benzocyanine compounds |
| WO2013130761A1 (en) | 2012-03-02 | 2013-09-06 | Pierce Biotechnology, Inc. | Indole derivatives as labeling dye for biomolecule |
| WO2013148319A1 (en) | 2012-03-30 | 2013-10-03 | Visen Medical, Inc. | Bacterial imaging agents and methods of using same |
| WO2013148038A1 (en) * | 2012-03-30 | 2013-10-03 | Life Technologies Corporation | Modified nucleic acid binding cyanine dyes for the detection of reactive oxygen species |
| AU2013303233C1 (en) | 2012-08-15 | 2018-08-23 | Visen Medical, Inc. | Prostate specific antigen agents and methods of using same for prostate cancer imaging |
| WO2014035712A1 (en) | 2012-08-28 | 2014-03-06 | Pierce Biotechnology, Inc. | Benzopyrylium compounds |
| EP2906106B1 (en) | 2012-10-15 | 2023-06-14 | VisEn Medical, Inc. | Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources |
| ES2628529T3 (es) | 2012-10-24 | 2017-08-03 | Tintes de cianina-azaindolina sustituidos con hidroxamato, y bioconjugados de los mismos | |
| NL2010040C2 (en) * | 2012-12-21 | 2014-06-24 | Internat Inst For Diagnostic And Analitical Affairs B V | Cleavable coating material having microbial functionality. |
| WO2014165216A1 (en) * | 2013-03-12 | 2014-10-09 | The Trustees Of The University Of Pennsylvania | Diagnosing and treating cancer |
| KR20160037834A (ko) | 2013-03-14 | 2016-04-06 | ๋ฃจ๋ฏธ์ , ์์ด์์จ. | ์๋ฃ ์ด๋ฏธ์ง ์ฅ์น ๋ฐ ์ฌ์ฉ ๋ฐฉ๋ฒ |
| JP6192799B2 (ja) * | 2013-03-15 | 2017-09-06 | ใใผใใฅใผใปใชใตใผใใปใใกใฆใณใใผใทใงใณ๏ผฐ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ ๏ผฒ๏ฝ ๏ฝ๏ฝ ๏ฝ๏ฝ๏ฝ๏ฝ ๏ผฆ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ | ่ ซ็ใฎๆจ็็ปๅๅใซไฝฟ็จใใใๅๅ็ฉใซใณใณใธใฅใฒใผใใใฆใใใขใใ้ ธ้ฃ็ตๅบใฎๅๆใใใณ็ตๆ็ฉ |
| CA2901000C (en) | 2013-03-15 | 2023-03-14 | Visen Medical, Inc. | 4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof |
| AU2014228504C1 (en) | 2013-03-15 | 2019-10-03 | Visen Medical, Inc. | Substituted silaxanthenium red to near-infrared fluorochromes for in vitro and in vivo imaging and detection |
| HK1221747A1 (zh) | 2013-07-30 | 2017-06-09 | ๅไฝๅญฆ้ข้ข้ฟๅ่ฃไบ | ๅบๆผdna็ๅฎ้ๆๅๅ่ถ ๅ่พจๆๅ |
| EP3019559A4 (en) | 2013-08-22 | 2017-04-05 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
| WO2015038968A1 (en) | 2013-09-13 | 2015-03-19 | The General Hospital Corporation | Activatable fibrin-binding probes |
| CN106455979A (zh) | 2013-12-31 | 2017-02-22 | ็บชๅฟตๆฏ้-ๅฏ็น็ณ็็ไธญๅฟ | ็จไบ่งๅ ๆบๅฎๆถๅค้้ๆๅ็็ณป็ปใๆนๆณๅ่ฎพๅค |
| KR101829159B1 (ko) | 2014-01-16 | 2018-02-13 | ์๋ ์ฃผ์ํ์ฌ | ์์ฉ์ฑ ํ๊ด ๋๋ ์ ์ ์ผ๋ฃ |
| JP6757255B2 (ja) | 2014-03-11 | 2020-09-16 | ใใฌใธใใณใ ใขใณใ ใใงใญใผใบ ใชใ ใใผใใผใ ใซใฌใใธ | ใใญใฐใฉใ ๅฏ่ฝใชๆ ธ้ ธใใญใผใใ็จใใ้ซในใซใผใใใๅใณ้ซๅบฆๅค้ๅใคใกใผใธใณใฐ |
| EP2944326B1 (en) * | 2014-05-16 | 2018-11-21 | Cyanagen Srl | Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases |
| ES2743458T5 (es) | 2014-08-08 | 2023-06-08 | Us Health | Eliminaciรณn fotocontrolada de dianas in vitro e in vivo |
| KR20170094268A (ko) | 2014-12-15 | 2017-08-17 | ๋ฉ๋ชจ๋ฆฌ์ผ ์ฌ๋ก์-์ผํฐ๋ง ์บ์ ์ผํฐ | ํฅ์๋ ์ ๊ฒฝ-๊ฒฐํฉ ์ ํ์ฑ์ ๊ฐ๋ ๊ณ ๋ฆฌํ ํฉํฐ๋, ์๊ธฐ ๊ณ ๋ฆฌํ ํฉํฐ๋์ ๊ฒฐํฉ๋ ๋๋ ธ์ ์, ๋ฐ ์ค์๊ฐ ์์ฒด๋ด ์ ๊ฒฝ ์กฐ์ง ์์ํ๋ฅผ ์ํ ์ด๋ค์ ์ฉ๋ |
| US10124111B2 (en) | 2015-02-24 | 2018-11-13 | The Board Of Trustees Of The Leland Stanford Junior University | Small molecule dye for molecular imaging and photothermal therapy |
| KR102676814B1 (ko) | 2015-02-26 | 2024-06-21 | ์๋๊ทธ๋ฃน์ฃผ์ํ์ฌ | ์ ํฉ ๊ทธ๋ฃน์ ํฌํจํ๋ ์์ฉ์ฑ ํ๊ด ๋๋ ์ฐฉ์ ์ผ๋ฃ |
| WO2016138457A1 (en) | 2015-02-26 | 2016-09-01 | Sony Corporation | Phenylethynylnaphthalene dyes and methods for their use |
| JP6849599B2 (ja) | 2015-05-11 | 2021-03-24 | ใฝใใผๆ ชๅผไผ็คพ | ่ถ ๆ่ฒใใคใใผใพใใฏใใชใใผๆๆ |
| KR102557419B1 (ko) | 2015-08-07 | 2023-07-19 | ํ๋ ์ง๋ํธ ์ค๋ ํ ๋ก์ฐ์ฆ ์ค๋ธ ํ๋ฐ๋ ์นผ๋ฆฌ์ง | ๋จ๋ฐฑ์ง-๋จ๋ฐฑ์ง ์ํธ์์ฉ์ ์ดํด์๋ ์์ํ |
| EP3331909A1 (en) | 2015-08-07 | 2018-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Near infrared photoimmunotherapy (nir-pit) of suppressor cells to treat cancer |
| CN114699525A (zh) | 2015-08-18 | 2022-07-05 | ไนๅคฉๅป่ฏ็ๆ่กไปฝๆ้ๅ ฌๅธ | ้ ่ๆๆๅถ่็ฉ็ๅถ้ ๆนๆณๅ็จณๅฎๅถ่็ฉ |
| EP3827846B1 (en) | 2015-08-18 | 2024-10-02 | Rakuten Medical, Inc. | Compositions, combinations and related methods for photoimmunotherapy |
| CN105199430B (zh) * | 2015-11-05 | 2017-03-22 | ๆตๅฎๅ่็็ฉ็งๆๆ้ๅ ฌๅธ | ไธ็งไธ็ฎ็ป็ปๆ่ฒๅๅๅ ถๅถๅคๆนๆณ |
| KR20180093961A (ko) | 2015-12-15 | 2018-08-22 | ๋ฉ๋ชจ๋ฆฌ์ผ ์ฌ๋ก์-์ผํฐ๋ง ์บ์ ์ผํฐ | ์กฐ์ง ๊ตฌ๋ณ, ์๋ฅผ ๋ค์ด, ์์ ์ค ์๊ฐํ๋ฅผ ์ํ ์์ํ ์์คํ ๋ฐ ๋ฐฉ๋ฒ |
| US11434377B2 (en) | 2016-04-01 | 2022-09-06 | Sony Corporation | Ultra bright dimeric or polymeric dyes with rigid spacing groups |
| KR102530707B1 (ko) | 2016-04-01 | 2023-05-11 | ์๋๊ทธ๋ฃน์ฃผ์ํ์ฌ | ์ดํ๋ ์ด๋์ฒด์ฑ ๋๋ ์คํฉ์ฒด์ฑ ์ผ๋ฃ |
| KR20180133890A (ko) | 2016-04-06 | 2018-12-17 | ์๋ ์ฃผ์ํ์ฌ | ์คํ์ด์ฑ ๋ง์ปค ๊ทธ๋ฃน์ ํฌํจํ๋ ์ด๊ณ ๋ช ๋ ์ด๋์ฒด์ฑ ๋๋ ์คํฉ์ฒด์ฑ ์ผ๋ฃ |
| WO2017196954A1 (en) | 2016-05-10 | 2017-11-16 | Sony Corporation | Ultra bright polymeric dyes with peptide backbones |
| WO2017197014A2 (en) | 2016-05-10 | 2017-11-16 | Sony Corporation | Compositions comprising a polymeric dye and a cyclodextrin and uses thereof |
| EP3455300A1 (en) | 2016-05-11 | 2019-03-20 | Sony Corporation | Ultra bright dimeric or polymeric dyes |
| JP7068191B2 (ja) | 2016-06-06 | 2022-05-16 | ใฝใใผใฐใซใผใๆ ชๅผไผ็คพ | ่ๅ ใพใใฏๆ่ฒใฌใใผใฟใผๅบใๅซใใคใชใณๆงใใชใใผ |
| US12018159B2 (en) | 2016-07-29 | 2024-06-25 | Sony Group Corporation | Ultra bright dimeric or polymeric dyes and methods for preparation of the same |
| WO2018102372A1 (en) | 2016-11-30 | 2018-06-07 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
| AU2017370751B2 (en) | 2016-12-09 | 2023-11-09 | Ultivue, Inc. | Improved methods for multiplex imaging using labeled nucleic acid imaging agents |
| EP3568689B1 (en) | 2017-01-10 | 2025-09-03 | Sun Chemical Corporation | In-line coating weight and radiant energy exposure measurement |
| JP7551056B2 (ja) | 2017-10-05 | 2024-09-17 | ใฝใใผใฐใซใผใๆ ชๅผไผ็คพ | ใใญใฐใฉใใใซใชใใชใใผ่ฌ็ฉ |
| EP3691689A1 (en) | 2017-10-05 | 2020-08-12 | Sony Corporation | Programmable dendritic drugs |
| CN111836645A (zh) | 2017-11-16 | 2020-10-27 | ็ดขๅฐผๅ ฌๅธ | ๅฏ็ผ็จ็่ๅ่ฏ็ฉ |
| WO2019140301A1 (en) | 2018-01-12 | 2019-07-18 | Sony Corporation | Polymers with rigid spacing groups comprising biologically active compounds |
| EP4616912A3 (en) | 2018-01-12 | 2025-11-19 | Sony Group Corporation | Phosphoalkyl ribose polymers comprising biologically active compounds |
| KR102742386B1 (ko) | 2018-03-19 | 2024-12-16 | ์๋๊ทธ๋ฃน์ฃผ์ํ์ฌ | ํ๊ด ์ ํธ ํฅ์์ ์ํ 2๊ฐ ๊ธ์์ ์ฌ์ฉ |
| WO2019182766A1 (en) | 2018-03-21 | 2019-09-26 | Sony Corporation | Polymeric tandem dyes with linker groups |
| EP3773153A4 (en) | 2018-03-30 | 2021-11-17 | Perkinelmer Health Sciences Inc. | SYSTEMS AND PROCEDURES FOR THE 3D RECONSTRUCTION OF ANATOMICAL ORGANS AND INCLUSIONS USING SHORT WAVE INFRARED (SWIR) PROJECTION STOMOGRAPHY |
| KR102854332B1 (ko) | 2018-06-27 | 2025-09-03 | ์๋๊ทธ๋ฃน์ฃผ์ํ์ฌ | ๋์ฅ์๋ฆฌ๋ณด์ค์ค๋ฅผ ํฌํจํ๋ ๋ง์ปค ๊ตฐ์ ๊ฐ๋ ์คํฉ์ฒด์ฑ ์ผ๋ฃ |
| KR102132885B1 (ko) * | 2018-09-03 | 2020-07-10 | (์ฃผ)์จ๋ฐ์ด์ค๋ฉ์ค | ์์ฒด๋ฌผ์ง๊ณผ ์ฐ๊ฒฐ๋ ์ ์๋ ์์ชฝ์ฑ ํ๊ด๋ฌผ์ง |
| KR102486779B1 (ko) | 2019-09-26 | 2023-01-12 | ์๋๊ทธ๋ฃน์ฃผ์ํ์ฌ | ๋ง์ปค ๊ทธ๋ฃน์ ๊ฐ๋ ์คํฉ์ฒด์ฑ ํ ๋ค ์ผ๋ฃ |
| KR102336507B1 (ko) * | 2020-02-21 | 2021-12-06 | ํ๋ฆผ๋ํ๊ต ์ฐํํ๋ ฅ๋จ | ๊ตญ์๋์ฐ์ํฌํ๋๋ฅผ ์ด์ฉํ ์ง์ฐ์ฑ ๋ํํ ์ง๋จ ๋ฐฉ๋ฒ |
| KR102369155B1 (ko) * | 2020-07-07 | 2022-02-28 | ํ๋ฆผ๋ํ๊ต ์ฐํํ๋ ฅ๋จ | ๊ทผ์ ์ธ์ ๋ถ๊ด๋ถ์๋ฒ์ ์ด์ฉํ ์ง์ฐ์ฑ ๋ํํ ์ง๋จ ๋ฐฉ๋ฒ |
| CN112062797B (zh) * | 2020-08-19 | 2021-09-21 | ๅๅ็ๅทฅๅคงๅญฆ | ไธ็งไบ่ไฝๅ่ฏๅๅ ถๅถๅคๆนๆณๅๅบ็จ |
| EP4256078A1 (en) | 2020-12-07 | 2023-10-11 | Sony Group Corporation | Spacing linker group design for brightness enhancement in dimeric or polymeric dyes |
| EP4015004A1 (en) | 2020-12-18 | 2022-06-22 | Phi Pharma SA | Proteoglycan specific branched peptides |
| CN114748640B (zh) * | 2022-05-06 | 2024-02-09 | ๅๆนๅป็งๅคงๅญฆ็ ๆฑๅป้ข | ไธ็งpHๅๅบๆง็siRNA้้็ณป็ป |
| EP4573360A1 (en) | 2023-01-26 | 2025-06-25 | Sun Chemical Corporation | Fluorescent ink and imaging system for defect detection on printed photosensitive objects |
| WO2025107185A1 (zh) * | 2023-11-22 | 2025-05-30 | ไธญๅฝ็งๅญฆ้ขๆทฑๅณๅ ่ฟๆๆฏ็ ็ฉถ้ข | ไธ็ง่ฝฝไฝใ้ถๅ็บณ็ฑณ้ข็ฒๅๅ ถๅถๅคๆนๆณๅๅบ็จ |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986001720A1 (en) * | 1984-09-13 | 1986-03-27 | Cytogen Corporation | Antibody therapeutic agent conjugates |
| US5569587A (en) | 1986-04-18 | 1996-10-29 | Carnegie Mellon University | Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes |
| US5066490A (en) * | 1988-06-01 | 1991-11-19 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Protein crosslinking reagents cleavable within acidified intracellular vesicles |
| CA2048089A1 (en) * | 1990-09-17 | 1992-03-18 | Wolfgang A. Wrasidlo | Chemical conjugation of morpholino anthracyclines to antibodies |
| JPH07145148A (ja) | 1992-06-02 | 1995-06-06 | Bio Sensor Kenkyusho:Kk | ใใชใกใใณ็ณปๅๅ็ฉใใใณใใใ็จใใๆธฌๅฎๆนๆณ |
| GB9310978D0 (en) * | 1993-05-27 | 1993-07-14 | Zeneca Ltd | Compounds |
| DE4445065A1 (de) * | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung |
| US5968479A (en) * | 1995-01-30 | 1999-10-19 | Daiichi Pure Chemicals Co., Ltd. | Diagnostic marker |
| US5741657A (en) * | 1995-03-20 | 1998-04-21 | The Regents Of The University Of California | Fluorogenic substrates for ฮฒ-lactamase and methods of use |
| IT1276833B1 (it) | 1995-10-09 | 1997-11-03 | Sorin Biomedica Cardio Spa | Coloranti fluorescenti della famiglia della solfo benz e indocianina |
| DE19539409C2 (de) * | 1995-10-11 | 1999-02-18 | Diagnostikforschung Inst | Kontrastmittel fรผr die Nahinfrarot-Diagnostik |
| WO1997040104A1 (en) * | 1996-04-19 | 1997-10-30 | Amersham Pharmacia Biotech Uk Limited | Squarate dyes and their use in fluorescent sequencing method |
| DE19649971A1 (de) * | 1996-11-19 | 1998-05-28 | Diagnostikforschung Inst | Optische Diagnostika zur Diagnostik neurodegenerativer Krankheiten mittels Nahinfrarot-Strahlung (NIR-Strahlung) |
| DE19717904A1 (de) * | 1997-04-23 | 1998-10-29 | Diagnostikforschung Inst | Sรคurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie |
| KR20050103308A (ko) | 2003-02-28 | 2005-10-28 | ์ ์ธํฐ๋์ตธ๋์๋ ๋ ์ฌ์์น ๋ง์์ธ ์คํผ ๋น์ด๋ถ์ด | ๋ฐฉ๋ฒ |
-
1997
- 1997-04-23 DE DE19717904A patent/DE19717904A1/de not_active Ceased
-
1998
- 1998-04-02 DK DK98929212T patent/DK0988060T3/da active
- 1998-04-02 CA CA002287262A patent/CA2287262C/en not_active Expired - Fee Related
- 1998-04-02 JP JP54471598A patent/JP5118790B2/ja not_active Expired - Fee Related
- 1998-04-02 AU AU79057/98A patent/AU733757B2/en not_active Ceased
- 1998-04-02 KR KR1019997009757A patent/KR100613306B1/ko not_active Expired - Fee Related
- 1998-04-02 DE DE59814030T patent/DE59814030D1/de not_active Expired - Lifetime
- 1998-04-02 PT PT98929212T patent/PT988060E/pt unknown
- 1998-04-02 CN CN98804489A patent/CN1253507A/zh active Pending
- 1998-04-02 HU HU0003132A patent/HU226812B1/hu not_active IP Right Cessation
- 1998-04-02 EP EP98929212A patent/EP0988060B1/de not_active Expired - Lifetime
- 1998-04-02 WO PCT/DE1998/001001 patent/WO1998047538A2/de not_active Ceased
- 1998-04-02 AT AT98929212T patent/ATE364404T1/de active
- 1998-04-02 ES ES98929212T patent/ES2289786T3/es not_active Expired - Lifetime
- 1998-04-02 US US09/403,418 patent/US6534041B1/en not_active Expired - Lifetime
-
1999
- 1999-10-22 NO NO19995181A patent/NO327495B1/no not_active IP Right Cessation
-
2007
- 2007-09-12 CY CY20071101174T patent/CY1106860T1/el unknown
-
2010
- 2010-01-26 JP JP2010014564A patent/JP2010116413A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT988060E (pt) | 2007-08-17 |
| JP2010116413A (ja) | 2010-05-27 |
| JP2001521530A (ja) | 2001-11-06 |
| JP5118790B2 (ja) | 2013-01-16 |
| WO1998047538A2 (de) | 1998-10-29 |
| NO995181L (no) | 1999-10-22 |
| HUP0003132A2 (hu) | 2001-01-29 |
| KR100613306B1 (ko) | 2006-08-17 |
| EP0988060A2 (de) | 2000-03-29 |
| NO327495B1 (no) | 2009-07-20 |
| US6534041B1 (en) | 2003-03-18 |
| AU733757B2 (en) | 2001-05-24 |
| CA2287262A1 (en) | 1998-10-29 |
| CA2287262C (en) | 2007-02-06 |
| DK0988060T3 (da) | 2007-10-15 |
| CN1253507A (zh) | 2000-05-17 |
| WO1998047538A3 (de) | 1999-01-21 |
| EP0988060B1 (de) | 2007-06-13 |
| CY1106860T1 (el) | 2012-05-23 |
| AU7905798A (en) | 1998-11-13 |
| ATE364404T1 (de) | 2007-07-15 |
| ES2289786T3 (es) | 2008-02-01 |
| NO995181D0 (no) | 1999-10-22 |
| HUP0003132A3 (en) | 2003-03-28 |
| DE59814030D1 (de) | 2007-07-26 |
| KR20010020183A (ko) | 2001-03-15 |
| DE19717904A1 (de) | 1998-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU226812B1 (en) | Enzymatically divisible dye compounds for diagnosis with near infrared light | |
| EP2035505B1 (en) | Optical fluorescent imaging using cyanine dyes | |
| EP2630196B1 (en) | Cyanine dyes and their conjugates | |
| EP1181940B1 (de) | Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung | |
| US5672333A (en) | Delta1,6 bicyclo 4,4,0! functional dyes for contrast enhancement in optical imaging | |
| US20040171827A1 (en) | Phthalocyanine dyes | |
| US6423547B1 (en) | Non-covalent bioconjugates useful for diagnosis and therapy | |
| JP2012524153A (ja) | ็ฝฎๆใทใขใใณๆๆใ็จใใ่ๅ ใคใกใผใธใณใฐ | |
| CA2272320A1 (en) | Optical diagnostic agents for diagnosis of neurodegenerative diseases by means of near infra-red radiation (nir radiation) | |
| KR20100017102A (ko) | ๊ดํ ์กฐ์์ | |
| NZ517944A (en) | Antibody dye conjugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries | |
| HK1027035A (en) | Acid-labile and enzymatically divisible dye compounds for diagnosis with near infrared light and for therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |